- call +1-201-465-4211
- email sales@mrinsights.biz
Central nervous system (CNS) disease is a broad category of conditions in which the brain does not function as it should, limiting health and the ability to function. The condition may be an inherited metabolic disorder; the result of damage from an infection, a degenerative condition, stroke, a brain tumor or other problem; or arise from unknown or multiple factors. Movement disorders such as Parkinson’s disease, dystonia, and essential tremor are central nervous system conditions. What they have in common is the loss of sufficient, intact nervous system circuits that orchestrate functions as varied as memory formation (in Alzheimer’s) or voluntary motion (in movement disorders).
Scope of the Report:
This report studies the CNS Therapeutics market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the CNS Therapeutics market by product type and applications/end industries.
Mental health segment accounted for the largest market share in 2016. It is expected to retain its dominance over the forecast period owing to developing therapeutic options for mental diseases such as personality disorders and binge eating disorders. This segment is followed by degenerative disorders segment. There is growing awareness regarding neurodegenerative diseases owing to increase in initiatives by government and nongovernment organizations, such as Alzheimer’s and Related Disorders Society of India. These organizations conduct awareness campaigns and conferences, such as Asia Pacific Conference of ADI at New Delhi and Kerala State Initiative on Dementia, which encourage the adoption of treatment for degenerative and mental disorders.
The global CNS Therapeutics market is valued at xx million USD in 2017 and is expected to reach xx million USD by the end of 2023, growing at a CAGR of xx% between 2017 and 2023.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of CNS Therapeutics.
Europe also play important roles in global market, with market size of xx million USD in 2017 and will be xx million USD in 2023, with a CAGR of xx%.
Market Segment by Companies, this report covers
Pfizer
Janssen Pharmaceuticals
Allergan
Lundbeck
Teva
Camber Pharmaceuticals
Zhejiang Haisen Pharmaceutical
Jewim Pharmaceutical
Cipla
Merck Sharp & Dohme Corp.
Eli Lilly
GlaxoSmithKline
Novartis
LUPIN
ZYDUS PHARMS
Biogen
Otsuka Pharmaceutical
Astra Zeneca
Shire
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Neurodegenerative Diseases
Mood Disorders
Schizophrenia
Autism
Depression
Market Segment by Applications, can be divided into
Hospital Use
Clinic Use
Household
Other
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 CNS Therapeutics Market Overview
1.1 Product Overview and Scope of CNS Therapeutics
1.2 Classification of CNS Therapeutics by Types
1.2.1 Global CNS Therapeutics Revenue Comparison by Types (2017-2023)
1.2.2 Global CNS Therapeutics Revenue Market Share by Types in 2017
1.2.3 Neurodegenerative Diseases
1.2.4 Mood Disorders
1.2.5 Schizophrenia
1.2.6 Autism
1.2.7 Depression
1.3 Global CNS Therapeutics Market by Application
1.3.1 Global CNS Therapeutics Market Size and Market Share Comparison by Applications (2013-2023)
1.3.2 Hospital Use
1.3.3 Clinic Use
1.3.4 Household
1.3.5 Other
1.4 Global CNS Therapeutics Market by Regions
1.4.1 Global CNS Therapeutics Market Size (Million USD) Comparison by Regions (2013-2023)
1.4.1 North America (USA, Canada and Mexico) CNS Therapeutics Status and Prospect (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy) CNS Therapeutics Status and Prospect (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) CNS Therapeutics Status and Prospect (2013-2023)
1.4.4 South America (Brazil, Argentina, Colombia) CNS Therapeutics Status and Prospect (2013-2023)
1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) CNS Therapeutics Status and Prospect (2013-2023)
1.5 Global Market Size of CNS Therapeutics (2013-2023)
2 Manufacturers Profiles
2.1 Pfizer
2.1.1 Business Overview
2.1.2 CNS Therapeutics Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Pfizer CNS Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.2 Janssen Pharmaceuticals
2.2.1 Business Overview
2.2.2 CNS Therapeutics Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Janssen Pharmaceuticals CNS Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.3 Allergan
2.3.1 Business Overview
2.3.2 CNS Therapeutics Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Allergan CNS Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.4 Lundbeck
2.4.1 Business Overview
2.4.2 CNS Therapeutics Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Lundbeck CNS Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.5 Teva
2.5.1 Business Overview
2.5.2 CNS Therapeutics Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 Teva CNS Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.6 Camber Pharmaceuticals
2.6.1 Business Overview
2.6.2 CNS Therapeutics Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 Camber Pharmaceuticals CNS Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.7 Zhejiang Haisen Pharmaceutical
2.7.1 Business Overview
2.7.2 CNS Therapeutics Type and Applications
2.7.2.1 Product A
2.7.2.2 Product B
2.7.3 Zhejiang Haisen Pharmaceutical CNS Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.8 Jewim Pharmaceutical
2.8.1 Business Overview
2.8.2 CNS Therapeutics Type and Applications
2.8.2.1 Product A
2.8.2.2 Product B
2.8.3 Jewim Pharmaceutical CNS Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.9 Cipla
2.9.1 Business Overview
2.9.2 CNS Therapeutics Type and Applications
2.9.2.1 Product A
2.9.2.2 Product B
2.9.3 Cipla CNS Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.10 Merck Sharp & Dohme Corp.
2.10.1 Business Overview
2.10.2 CNS Therapeutics Type and Applications
2.10.2.1 Product A
2.10.2.2 Product B
2.10.3 Merck Sharp & Dohme Corp. CNS Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.11 Eli Lilly
2.11.1 Business Overview
2.11.2 CNS Therapeutics Type and Applications
2.11.2.1 Product A
2.11.2.2 Product B
2.11.3 Eli Lilly CNS Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.12 GlaxoSmithKline
2.12.1 Business Overview
2.12.2 CNS Therapeutics Type and Applications
2.12.2.1 Product A
2.12.2.2 Product B
2.12.3 GlaxoSmithKline CNS Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.13 Novartis
2.13.1 Business Overview
2.13.2 CNS Therapeutics Type and Applications
2.13.2.1 Product A
2.13.2.2 Product B
2.13.3 Novartis CNS Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.14 LUPIN
2.14.1 Business Overview
2.14.2 CNS Therapeutics Type and Applications
2.14.2.1 Product A
2.14.2.2 Product B
2.14.3 LUPIN CNS Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.15 ZYDUS PHARMS
2.15.1 Business Overview
2.15.2 CNS Therapeutics Type and Applications
2.15.2.1 Product A
2.15.2.2 Product B
2.15.3 ZYDUS PHARMS CNS Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.16 Biogen
2.16.1 Business Overview
2.16.2 CNS Therapeutics Type and Applications
2.16.2.1 Product A
2.16.2.2 Product B
2.16.3 Biogen CNS Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.17 Otsuka Pharmaceutical
2.17.1 Business Overview
2.17.2 CNS Therapeutics Type and Applications
2.17.2.1 Product A
2.17.2.2 Product B
2.17.3 Otsuka Pharmaceutical CNS Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.18 Astra Zeneca
2.18.1 Business Overview
2.18.2 CNS Therapeutics Type and Applications
2.18.2.1 Product A
2.18.2.2 Product B
2.18.3 Astra Zeneca CNS Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.19 Shire
2.19.1 Business Overview
2.19.2 CNS Therapeutics Type and Applications
2.19.2.1 Product A
2.19.2.2 Product B
2.19.3 Shire CNS Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
3 Global CNS Therapeutics Market Competition, by Players
3.1 Global CNS Therapeutics Revenue and Share by Players (2013-2018)
3.2 Market Concentration Rate
3.2.1 Top 5 CNS Therapeutics Players Market Share
3.2.2 Top 10 CNS Therapeutics Players Market Share
3.3 Market Competition Trend
4 Global CNS Therapeutics Market Size by Regions
4.1 Global CNS Therapeutics Revenue and Market Share by Regions
4.2 North America CNS Therapeutics Revenue and Growth Rate (2013-2018)
4.3 Europe CNS Therapeutics Revenue and Growth Rate (2013-2018)
4.4 Asia-Pacific CNS Therapeutics Revenue and Growth Rate (2013-2018)
4.5 South America CNS Therapeutics Revenue and Growth Rate (2013-2018)
4.6 Middle East and Africa CNS Therapeutics Revenue and Growth Rate (2013-2018)
5 North America CNS Therapeutics Revenue by Countries
5.1 North America CNS Therapeutics Revenue by Countries (2013-2018)
5.2 USA CNS Therapeutics Revenue and Growth Rate (2013-2018)
5.3 Canada CNS Therapeutics Revenue and Growth Rate (2013-2018)
5.4 Mexico CNS Therapeutics Revenue and Growth Rate (2013-2018)
6 Europe CNS Therapeutics Revenue by Countries
6.1 Europe CNS Therapeutics Revenue by Countries (2013-2018)
6.2 Germany CNS Therapeutics Revenue and Growth Rate (2013-2018)
6.3 UK CNS Therapeutics Revenue and Growth Rate (2013-2018)
6.4 France CNS Therapeutics Revenue and Growth Rate (2013-2018)
6.5 Russia CNS Therapeutics Revenue and Growth Rate (2013-2018)
6.6 Italy CNS Therapeutics Revenue and Growth Rate (2013-2018)
7 Asia-Pacific CNS Therapeutics Revenue by Countries
7.1 Asia-Pacific CNS Therapeutics Revenue by Countries (2013-2018)
7.2 China CNS Therapeutics Revenue and Growth Rate (2013-2018)
7.3 Japan CNS Therapeutics Revenue and Growth Rate (2013-2018)
7.4 Korea CNS Therapeutics Revenue and Growth Rate (2013-2018)
7.5 India CNS Therapeutics Revenue and Growth Rate (2013-2018)
7.6 Southeast Asia CNS Therapeutics Revenue and Growth Rate (2013-2018)
8 South America CNS Therapeutics Revenue by Countries
8.1 South America CNS Therapeutics Revenue by Countries (2013-2018)
8.2 Brazil CNS Therapeutics Revenue and Growth Rate (2013-2018)
8.3 Argentina CNS Therapeutics Revenue and Growth Rate (2013-2018)
8.4 Colombia CNS Therapeutics Revenue and Growth Rate (2013-2018)
9 Middle East and Africa Revenue CNS Therapeutics by Countries
9.1 Middle East and Africa CNS Therapeutics Revenue by Countries (2013-2018)
9.2 Saudi Arabia CNS Therapeutics Revenue and Growth Rate (2013-2018)
9.3 UAE CNS Therapeutics Revenue and Growth Rate (2013-2018)
9.4 Egypt CNS Therapeutics Revenue and Growth Rate (2013-2018)
9.5 Nigeria CNS Therapeutics Revenue and Growth Rate (2013-2018)
9.6 South Africa CNS Therapeutics Revenue and Growth Rate (2013-2018)
10 Global CNS Therapeutics Market Segment by Type
10.1 Global CNS Therapeutics Revenue and Market Share by Type (2013-2018)
10.2 Global CNS Therapeutics Market Forecast by Type (2018-2023)
10.3 Neurodegenerative Diseases Revenue Growth Rate (2013-2023)
10.4 Mood Disorders Revenue Growth Rate (2013-2023)
10.5 Schizophrenia Revenue Growth Rate (2013-2023)
10.6 Autism Revenue Growth Rate (2013-2023)
10.7 Depression Revenue Growth Rate (2013-2023)
11 Global CNS Therapeutics Market Segment by Application
11.1 Global CNS Therapeutics Revenue Market Share by Application (2013-2018)
11.2 CNS Therapeutics Market Forecast by Application (2018-2023)
11.3 Hospital Use Revenue Growth (2013-2018)
11.4 Clinic Use Revenue Growth (2013-2018)
11.5 Household Revenue Growth (2013-2018)
11.6 Other Revenue Growth (2013-2018)
12 Global CNS Therapeutics Market Size Forecast (2018-2023)
12.1 Global CNS Therapeutics Market Size Forecast (2018-2023)
12.2 Global CNS Therapeutics Market Forecast by Regions (2018-2023)
12.3 North America CNS Therapeutics Revenue Market Forecast (2018-2023)
12.4 Europe CNS Therapeutics Revenue Market Forecast (2018-2023)
12.5 Asia-Pacific CNS Therapeutics Revenue Market Forecast (2018-2023)
12.6 South America CNS Therapeutics Revenue Market Forecast (2018-2023)
12.7 Middle East and Africa CNS Therapeutics Revenue Market Forecast (2018-2023)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
List of Tables and Figures
Figure CNS Therapeutics Picture
Table Product Specifications of CNS Therapeutics
Table Global CNS Therapeutics and Revenue (Million USD) Market Split by Product Type
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
